No Data
Black Hawk Acquisition, Vesicor Deal Values Vesicor at Pre-Money Equity Value of $70M
Black Hawk Acquisition to Continue to Be Listed on Nasdaq, Change Name to Vesicor Therapeutics
Vesicor to Become Wholly Owned Subsidiary of Black Hawk
Press Release: Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter Into a Business Combination Agreement to Create a Biotechnology Company Advancing P53-based Cancer Therapeutics Delivered Via Microvesicles
Metal Hawk Ltd. Approves Key Resolutions at Extraordinary General Meeting
Hawk Resources Identifies Significant Copper Anomalies at Cactus Project
